Patents by Inventor Marcus Korn

Marcus Korn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin analogs with reduced affinity to insulin receptor and use thereof
    Patent number: 11396534
    Abstract: The present invention relates to a novel insulin analog, use thereof, and a method for preparing the analog.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: July 26, 2022
    Assignees: HANMI PHARM. CO., LTD., SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: In Young Choi, Sung Youb Jung, Marcus Korn, Stefan Guessregen, Norbert Tennagels
  • INSULIN ANALOGS WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND USE THEREOF
    Publication number: 20190300593
    Abstract: The present invention relates to a novel insulin analog, use thereof, and a method for preparing the analog.
    Type: Application
    Filed: September 22, 2017
    Publication date: October 3, 2019
    Applicants: HANMI PHARM. CO., LTD., Sanofi-Aventis Deutschland GmbH
    Inventors: In Young CHOI, Sung Youb JUNG, Marcus KORN, Stefan GUESSREGEN, Norbert TENNAGELS
  • PIM-3 kinase as a target for type 2 diabetes mellitus
    Patent number: 7227006
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: June 5, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marcus Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank